Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaxolone - Marinus Pharmaceuticals

Next Previous
Drug Profile

Ganaxolone - Marinus Pharmaceuticals

Alternative Names: CCD-1042; Ganaxalone-IV; gnx; GNX oral suspension - Marinus Pharmaceuticals; ZTALMY

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals; Purdue Pharma; Tenacia Biotechnology
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Ketones; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Fragile X syndrome; Epilepsy; Early infantile epileptic encephalopathy 2; Infantile spasms; Tuberous sclerosis; Lennox-Gastaut syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Early infantile epileptic encephalopathy 2
  • Phase III Status epilepticus
  • Phase II Epilepsy; Fragile X syndrome
  • Phase I Lennox-Gastaut syndrome
  • Suspended Major depressive disorder; Postnatal depression
  • Discontinued Angelman syndrome; Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies; Post-traumatic stress disorders; Tuberous sclerosis

Most Recent Events

  • 18 Sep 2025 Discontinued - Preclinical for Angelman syndrome in USA (unspecified route)
  • 25 Jun 2025 Immedica in-licenses ganaxolone from Ovid Therapeutics for countries outside of China
  • 11 Feb 2025 Marinus Pharmaceuticals has been acquired by Immedica

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top